ArticleClinical pharmacology and therapeutics2013
CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality.
Article in Clinical pharmacology and therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application.The pharmacogenomics journal · 2021Pooled it
- Review
- Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Article
- A Review of the Important Role ofGenes · 2020Review
- Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen.Frontiers in pharmacology · 2020Article
- Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.Clinical and translational science · 2018Article
- Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.Clinical pharmacokinetics · 2018Article
- CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.Breast cancer research and treatment · 2017Article
- CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.Scientific reports · 2017Article
- Effects ofBreast cancer (Dove Medical Press) · 2017Article
- Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.Frontiers in pharmacology · 2017Article
- Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment.Breast cancer (Dove Medical Press) · 2016Article
- Endocrine resistance in breast cancer--An overview and update.Molecular and cellular endocrinology · 2015Review
- Pharmacogenomics in the clinic.Nature · 2015Review
- Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.Clinical pharmacokinetics · 2015Review
- Addressing phenoconversion: the Achilles' heel of personalized medicine.British journal of clinical pharmacology · 2015Review
- Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.The pharmacogenomics journal · 2015Observational
- CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies.Clinical pharmacology and therapeutics · 2014Review
- CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply.British journal of clinical pharmacology · 2014Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.